We addressed potential therapeutic interest of celastrol in PH-BPD.

Different concentrations of celastrol (0,1–0,5–1 mg/kg/d) were tested in a murine model of hyperoxic PH-BPD (14 days with 90% O2–Hx). We evaluated hemodynamic parameters with echocardiography, lung remodeling with histological methods and pulmonary arterial (PA) reactivity with myograph. Cytoplasmic calcium (Ca2+i) response to endothelin-1 (ET-1) was evaluated in human fetal PA smooth muscle cells (fPASMC) with spectrophotometry in normoxic (21% O2) and Hx conditions (48 h with 60% O2). Inflammation and oxidant stress were also addressed.

Celastrol reduces mortality at doses of 1 and 0,5 mg/kg/d compared to Hx control. At 1 mg/kg/d, it normalizes PA acceleration time and reduces vascular hyperreactivity to ET-1 inversely to phenylephrine and 5-HT, with no effect on the altered response to acetylcholine induced by Hx. At all doses, it decreases right heart hypertrophy and vascular remodeling but has no effect on media cells proliferation observed in Hx condition. It has also no impact on alveolarization and vascular density. Although celastrol (0.1 and 0.3 μM) decreases the increased Ca2+i response to ET-1 in Hx in fPASMC, expression of ET-1 receptors was unchanged. In fPASMC, celastrol 0.3 μM decreases the increased concentration of IL6 observed in Hx but has no effect on IL8 and MIF. In both models, Hx-induced oxidant stress remains mild with absence of protein carbonylation and lipid peroxidation and celastrol at 1 mg/kg/d increases heme oxygenase 1 expression.

Celastrol has a preventive dose-dependent effect on major hallmarks of PH induced by Hx and could be considered as a new potential therapeutic option for PH-BPD.

The authors have not supplied their declaration of competing interest.

Copyright © 2023 Published by Elsevier Masson SAS